{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825895487010048.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/s0014-2999(02)02666-3"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0014299902026663?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0014299902026663?httpAccept=text/plain"}},{"identifier":{"@type":"PMID","@value":"12460639"}}],"dc:title":[{"@value":"Inhibitory effect of the class III antiarrhythmic drug nifekalant on HERG channels: mode of action"}],"description":[{"notation":[{"@value":"Nifekalant is a class III antiarrhythmic drug that has been shown to be effective against ventricular tachyarrhythmias in experimental animals and humans. We examined the detailed electrophysiological effects of nifekalant on human-ether-a-go-go-related gene (HERG) channels expressed in Xenopus oocytes. Nifekalant inhibited the HERG current in a concentration-dependent manner with an IC(50) value of 7.9 microM although the drug did not inhibit the minK current in Xenopus oocytes, suggesting selective inhibition of the rapid component of the delayed rectifier K(+) current (I(Kr)) in cardiomyocytes. Nifekalant showed a higher binding affinity for the open state than for the inactive state of HERG channels. Nifekalant inhibited HERG channels in a frequency-dependent manner. The onset of the blockade was rapid but the recovery from the block was slow. Nifekalant modified the voltage dependence and kinetics of HERG channel gating. Thus, nifekalant inhibits HERG channels in a voltage-dependent and frequency-dependent manner, and the inhibitory effect may underlie the clinical efficacy of the drug against ventricular tachyarrhythmias."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382825895487010048","@type":"Researcher","foaf:name":[{"@value":"Shunichi Kushida"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895487010051","@type":"Researcher","foaf:name":[{"@value":"Takehiko Ogura"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895487010049","@type":"Researcher","foaf:name":[{"@value":"Issei Komuro"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825895487010050","@type":"Researcher","foaf:name":[{"@value":"Haruaki Nakaya"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00142999"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/0021793X"}],"prism:publicationName":[{"@value":"European Journal of Pharmacology"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2002-12","prism:volume":"457","prism:number":"1","prism:startingPage":"19","prism:endingPage":"27"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0014299902026663?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0014299902026663?httpAccept=text/plain"}],"createdAt":"2002-12-03","modifiedAt":"2025-09-15","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Patch-Clamp%20Techniques","dc:title":"Patch-Clamp Techniques"},{"@id":"https://cir.nii.ac.jp/all?q=Potassium%20Channels","dc:title":"Potassium Channels"},{"@id":"https://cir.nii.ac.jp/all?q=Dose-Response%20Relationship,%20Drug","dc:title":"Dose-Response Relationship, Drug"},{"@id":"https://cir.nii.ac.jp/all?q=Pyrimidinones","dc:title":"Pyrimidinones"},{"@id":"https://cir.nii.ac.jp/all?q=In%20Vitro%20Techniques","dc:title":"In Vitro Techniques"},{"@id":"https://cir.nii.ac.jp/all?q=Ether-A-Go-Go%20Potassium%20Channels","dc:title":"Ether-A-Go-Go Potassium Channels"},{"@id":"https://cir.nii.ac.jp/all?q=Kinetics","dc:title":"Kinetics"},{"@id":"https://cir.nii.ac.jp/all?q=Xenopus%20laevis","dc:title":"Xenopus laevis"},{"@id":"https://cir.nii.ac.jp/all?q=Potassium%20Channels,%20Voltage-Gated","dc:title":"Potassium Channels, Voltage-Gated"},{"@id":"https://cir.nii.ac.jp/all?q=Oocytes","dc:title":"Oocytes"},{"@id":"https://cir.nii.ac.jp/all?q=Potassium%20Channel%20Blockers","dc:title":"Potassium Channel Blockers"},{"@id":"https://cir.nii.ac.jp/all?q=Animals","dc:title":"Animals"},{"@id":"https://cir.nii.ac.jp/all?q=Anti-Arrhythmia%20Agents","dc:title":"Anti-Arrhythmia Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Cation%20Transport%20Proteins","dc:title":"Cation Transport Proteins"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360017279869338752","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Structural modeling of the hERG potassium channel and associated drug interactions"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285711678100736","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Development of Recombinant Cell Line Co-expressing Mutated Nav1.5, Kir2.1, and hERG for the Safety Assay of Drug Candidates"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302865550086400","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Structural modeling of hERG channel–drug interactions using Rosetta"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565165776405888","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A mechanism underlying compound-induced voltage shift in the current activation of hERG by antiarrhythmic agents"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205104876288","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Combined Effects of Nifekalant and Lidocaine on the Spiral-Type Re-Entry in a Perfused 2-Dimensional Layer of Rabbit Ventricular Myocardium"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205226695168","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effect of the ATP-Sensitive K+ Channel Opener Nicorandil in a Canine Model of Proarrhythmia"},{"@value":"Effect of ATP-sensitive K+ channel opener nicorandil in a canine model of proarrhythmia"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680082173824","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Can Nifekalant Hydrochloride be Used as a First-Line Drug for Cardiopulmonary Arrest (CPA)?"}]},{"@id":"https://cir.nii.ac.jp/crid/1390294562485513984","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pore opening, not voltage sensor movement, underpins the voltage-dependence of facilitation by a hERG blocker."},{"@language":"ja","@value":"電位センサーの移動ではなく、細孔の開口がhERG阻害剤による促進作用の電位依存性を生み出している"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/s0014-2999(02)02666-3"},{"@type":"OPENAIRE","@value":"doi_dedup___::551d69d536019d4a016b4a5c604ac794"},{"@type":"CROSSREF","@value":"10.1253/circj.69.576_references_DOI_KY1qZzYVnDpB7OreowNk0CgxtMx"},{"@type":"CROSSREF","@value":"10.1177/1087057112442102_references_DOI_KY1qZzYVnDpB7OreowNk0CgxtMx"},{"@type":"CROSSREF","@value":"10.1016/j.bbrc.2011.10.034_references_DOI_KY1qZzYVnDpB7OreowNk0CgxtMx"},{"@type":"CROSSREF","@value":"10.3389/fphar.2023.1244166_references_DOI_TUPVMzWETDqszlLXKMIoboXsxWz"},{"@type":"CROSSREF","@value":"10.1536/ihj.52.318_references_DOI_KY1qZzYVnDpB7OreowNk0CgxtMx"},{"@type":"CROSSREF","@value":"10.1101/2021.07.08.451699_references_DOI_KY1qZzYVnDpB7OreowNk0CgxtMx"},{"@type":"CROSSREF","@value":"10.1124/molpharm.122.000569_references_DOI_KY1qZzYVnDpB7OreowNk0CgxtMx"},{"@type":"CROSSREF","@value":"10.1253/circj.70.21_references_DOI_KY1qZzYVnDpB7OreowNk0CgxtMx"}]}